SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.
Authors:
- Hanna PisarekHPHanna Pisarek
- Marek PawlikowskiMPMarek Pawlikowski
- Jolanta Kunert-RadekJKJolanta Kunert-Radek
- Robert KubiakRKRobert Kubiak
- Katarzyna WinczykKWKatarzyna Winczyk
Open Access
- 10 June 2010
- journal article
- Published by VM Media Group sp. z o.o in Folia Histochemica et Cytobiologica
- Vol. 48 (1) , 142-147
Abstract
SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.Keywords
This publication has 19 references indexed in Scilit:
- Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigationThyroid Research, 2009
- Somatostatin receptors in human adrenal gland tumors--immunohistochemical study.Folia Histochemica et Cytobiologica, 2008
- Somatostatin Analogs in Diagnostics and Therapy2007
- Somatostatin receptor imaging for neuroendocrine tumorsPituitary, 2006
- Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic systemAnnals of Oncology, 2004
- Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.Endocrine-Related Cancer, 2003
- AnIn VivoOctreoScan-Negative Adrenal Pheochromocytoma Expresses Somatostatin Receptors and Responds to Somatostatin Analogs TreatmentIn VitroHormone and Metabolic Research, 2003
- Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatmentCurrent Opinion in Oncology, 2002
- Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligandsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993